Effects of L-arginine on refolding of lysine-tagged human insulin-like growth factor 1 expressed in Escherichia coli

Seung Phill Choi, Yong Cheol Park, Jung Hwa Lee, Sang Jun Sim, Ho Nam Chang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Insulin-like growth factor 1 (IGF1), a therapeutic protein, is highly homologous to proinsulin in 3-dimensional structure. To highly express IGF1 in recombinant Escherichia coli, IGF1 was engineered to be fused with the 6-lysine tag and ubiquitin at its N-terminus (K6Ub-IGF1). Fed-batch fermentation of E. coli TG1/ pAPT-K6Ub-IGF1 resulted in 60.8 g/L of dry cell mass, 18% of which was inclusion bodies composed of K6Ub- IGF1. Subsequent refolding processes were conducted using accumulated inclusion bodies. An environment of 50 mM bicine buffer (pH 8.5), 125 mM L-arginine, and 4 °C was chosen to optimize the refolding of K6Ub-IGF1, and 240 mg/L of denatured K6Ub-IGF1 was refolded with a 32% yield. The positive effect of L-arginine on K6Ub- IGF1 refolding might be ascribed to preventing unfolded K6Ub-IGF1 from undergoing self-aggregation and thus increasing its solubility. The simple dilution refolding, followed by cleavage of the fusion protein by site-specific UBP1 and chromatographic purification of IGF1, led production of authentic IGF1 with 97% purity and an 8.5% purification yield, starting from 500 mg of inclusion bodies composed of K6Ub-IGF1, as verified by various analytical tools, such as RP-HPLC, CD spectroscopy, MALDI-TOF mass spectrometry, and Western blotting. Thus, it was confirmed that L-arginine with an aggregation-protecting ability could be applied to the development of refolding processes for other inclusion body-derived proteins.

Original languageEnglish
Pages (from-to)255-263
Number of pages9
JournalBioprocess and Biosystems Engineering
Volume35
Issue number1-2
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Arginine
Insulin
Somatomedins
Escherichia coli
Lysine
Inclusion Bodies
Proteins
Intercellular Signaling Peptides and Proteins
Purification
Agglomeration
Proinsulin
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Ubiquitin
Solubility
Fermentation
Dilution
Mass spectrometry
Mass Spectrometry
Spectrum Analysis
Buffers

Keywords

  • Inclusion body
  • Insulin-like growth factor 1
  • L-arginine
  • Refolding

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering

Cite this

Effects of L-arginine on refolding of lysine-tagged human insulin-like growth factor 1 expressed in Escherichia coli. / Choi, Seung Phill; Park, Yong Cheol; Lee, Jung Hwa; Sim, Sang Jun; Chang, Ho Nam.

In: Bioprocess and Biosystems Engineering, Vol. 35, No. 1-2, 01.01.2012, p. 255-263.

Research output: Contribution to journalArticle

@article{61f7c6653bcf4d789a7c0e145fbdd151,
title = "Effects of L-arginine on refolding of lysine-tagged human insulin-like growth factor 1 expressed in Escherichia coli",
abstract = "Insulin-like growth factor 1 (IGF1), a therapeutic protein, is highly homologous to proinsulin in 3-dimensional structure. To highly express IGF1 in recombinant Escherichia coli, IGF1 was engineered to be fused with the 6-lysine tag and ubiquitin at its N-terminus (K6Ub-IGF1). Fed-batch fermentation of E. coli TG1/ pAPT-K6Ub-IGF1 resulted in 60.8 g/L of dry cell mass, 18{\%} of which was inclusion bodies composed of K6Ub- IGF1. Subsequent refolding processes were conducted using accumulated inclusion bodies. An environment of 50 mM bicine buffer (pH 8.5), 125 mM L-arginine, and 4 °C was chosen to optimize the refolding of K6Ub-IGF1, and 240 mg/L of denatured K6Ub-IGF1 was refolded with a 32{\%} yield. The positive effect of L-arginine on K6Ub- IGF1 refolding might be ascribed to preventing unfolded K6Ub-IGF1 from undergoing self-aggregation and thus increasing its solubility. The simple dilution refolding, followed by cleavage of the fusion protein by site-specific UBP1 and chromatographic purification of IGF1, led production of authentic IGF1 with 97{\%} purity and an 8.5{\%} purification yield, starting from 500 mg of inclusion bodies composed of K6Ub-IGF1, as verified by various analytical tools, such as RP-HPLC, CD spectroscopy, MALDI-TOF mass spectrometry, and Western blotting. Thus, it was confirmed that L-arginine with an aggregation-protecting ability could be applied to the development of refolding processes for other inclusion body-derived proteins.",
keywords = "Inclusion body, Insulin-like growth factor 1, L-arginine, Refolding",
author = "Choi, {Seung Phill} and Park, {Yong Cheol} and Lee, {Jung Hwa} and Sim, {Sang Jun} and Chang, {Ho Nam}",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s00449-011-0619-7",
language = "English",
volume = "35",
pages = "255--263",
journal = "Bioprocess and Biosystems Engineering",
issn = "1615-7591",
publisher = "Springer Verlag",
number = "1-2",

}

TY - JOUR

T1 - Effects of L-arginine on refolding of lysine-tagged human insulin-like growth factor 1 expressed in Escherichia coli

AU - Choi, Seung Phill

AU - Park, Yong Cheol

AU - Lee, Jung Hwa

AU - Sim, Sang Jun

AU - Chang, Ho Nam

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Insulin-like growth factor 1 (IGF1), a therapeutic protein, is highly homologous to proinsulin in 3-dimensional structure. To highly express IGF1 in recombinant Escherichia coli, IGF1 was engineered to be fused with the 6-lysine tag and ubiquitin at its N-terminus (K6Ub-IGF1). Fed-batch fermentation of E. coli TG1/ pAPT-K6Ub-IGF1 resulted in 60.8 g/L of dry cell mass, 18% of which was inclusion bodies composed of K6Ub- IGF1. Subsequent refolding processes were conducted using accumulated inclusion bodies. An environment of 50 mM bicine buffer (pH 8.5), 125 mM L-arginine, and 4 °C was chosen to optimize the refolding of K6Ub-IGF1, and 240 mg/L of denatured K6Ub-IGF1 was refolded with a 32% yield. The positive effect of L-arginine on K6Ub- IGF1 refolding might be ascribed to preventing unfolded K6Ub-IGF1 from undergoing self-aggregation and thus increasing its solubility. The simple dilution refolding, followed by cleavage of the fusion protein by site-specific UBP1 and chromatographic purification of IGF1, led production of authentic IGF1 with 97% purity and an 8.5% purification yield, starting from 500 mg of inclusion bodies composed of K6Ub-IGF1, as verified by various analytical tools, such as RP-HPLC, CD spectroscopy, MALDI-TOF mass spectrometry, and Western blotting. Thus, it was confirmed that L-arginine with an aggregation-protecting ability could be applied to the development of refolding processes for other inclusion body-derived proteins.

AB - Insulin-like growth factor 1 (IGF1), a therapeutic protein, is highly homologous to proinsulin in 3-dimensional structure. To highly express IGF1 in recombinant Escherichia coli, IGF1 was engineered to be fused with the 6-lysine tag and ubiquitin at its N-terminus (K6Ub-IGF1). Fed-batch fermentation of E. coli TG1/ pAPT-K6Ub-IGF1 resulted in 60.8 g/L of dry cell mass, 18% of which was inclusion bodies composed of K6Ub- IGF1. Subsequent refolding processes were conducted using accumulated inclusion bodies. An environment of 50 mM bicine buffer (pH 8.5), 125 mM L-arginine, and 4 °C was chosen to optimize the refolding of K6Ub-IGF1, and 240 mg/L of denatured K6Ub-IGF1 was refolded with a 32% yield. The positive effect of L-arginine on K6Ub- IGF1 refolding might be ascribed to preventing unfolded K6Ub-IGF1 from undergoing self-aggregation and thus increasing its solubility. The simple dilution refolding, followed by cleavage of the fusion protein by site-specific UBP1 and chromatographic purification of IGF1, led production of authentic IGF1 with 97% purity and an 8.5% purification yield, starting from 500 mg of inclusion bodies composed of K6Ub-IGF1, as verified by various analytical tools, such as RP-HPLC, CD spectroscopy, MALDI-TOF mass spectrometry, and Western blotting. Thus, it was confirmed that L-arginine with an aggregation-protecting ability could be applied to the development of refolding processes for other inclusion body-derived proteins.

KW - Inclusion body

KW - Insulin-like growth factor 1

KW - L-arginine

KW - Refolding

UR - http://www.scopus.com/inward/record.url?scp=84857448424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857448424&partnerID=8YFLogxK

U2 - 10.1007/s00449-011-0619-7

DO - 10.1007/s00449-011-0619-7

M3 - Article

VL - 35

SP - 255

EP - 263

JO - Bioprocess and Biosystems Engineering

JF - Bioprocess and Biosystems Engineering

SN - 1615-7591

IS - 1-2

ER -